Showing results (101-110 of 156) with videos related to

Sort By:
Pageof 16
Molecular Genetics and Metabolism|January 12, 2016
Lyso-glycosphingolipid abnormalities in different murine models of lysosomal storage disordersMaria J Ferraz, André R A Marques, Paulo Gaspar, et al.
Haematologica|September 26, 2008
The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemiaCarlos Santamaría, María Carmen Chillón, Ramón García-Sanz, et al.
Chembiochem : a European Journal of Chemical Biology|April 23, 2013
Bicyclic derivatives of L-idonojirimycin as pharmacological chaperones for neuronopathic forms of Gaucher diseasePilar Alfonso, Vanesa Andreu, Almudena Pino-Angeles, et al.
Medicina Clinica|February 26, 2017
Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemiaJosé A García-Marco, Julio Delgado, José A Hernández-Rivas, et al.
American Journal of Hematology|May 14, 2016
Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher diseaseAri Zimran, Gloria Durán, Atul Mehta, et al.
European Journal of Haematology|May 17, 2012
Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangementMaryam Arefi, Juan L García, María J Peñarrubia, et al.
Hematological Oncology|July 5, 2021
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access studyFrancesco Passamonti, Vikas Gupta, Bruno Martino, et al.
Annals of Hematology|March 22, 2006
Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patientsFrancisco Javier Peñalver, Victor Jiménez-Yuste, Manuel Almagro, et al.
Haematologica|February 19, 2011
Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE projectRafael Marcos-Gragera, Claudia Allemani, Carmen Tereanu, et al.
Leukemia & Lymphoma|March 19, 2024
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trialVikas Gupta, Stephen Oh, Timothy Devos, et al.
Pageof 16